top of page

Madrigal's CEO discusses the NASH field ahead of a key FDA decision date in March

Bill Sibold describes how resmetirom acts on fibrosis and could be the first commercial product in NASH if approved by its March 14th decision date.

Join the BiotechTV mailing list

Thanks for subscribing!

bottom of page